Stock Price & Analysis

Based on the available data and recent market developments, here's a comprehensive analysis of EW stock:

Technical Analysis

The stock is currently showing mixed technical signals:

• Current price at $74.33 in pre-market trading, up 0.95%
• Trading below both 200-day SMA ($74.68) and 250-day SMA ($77.73)
• RSI-14 at 51.71 indicates neutral momentum
• MACD showing positive divergence with MACD at 0.81 and signal at 0.56

Recent Performance & News

• Q4 2024 Results:
  • Revenue: $1.39 billion (beat consensus of $1.36 billion)
  • Adjusted EPS: $0.59 (beat consensus of $0.55)
  • TAVR sales grew 5.3% YoY to $1.04 billion
  • TMTT sales reached $105 million with strong adoption

Insider Activity

Recent insider selling activity raises some concerns:

• CVP Scott B. Ullem sold 11,250 shares on Feb 13, 2025
• 17 insider sales and 0 purchases in past 6 months
• Institutional investors: 480 increased positions vs 781 decreased

Valuation Metrics

Growth Outlook

Management guidance for 2025:

• Q1 2025 adjusted EPS: $0.58-0.64 (consensus: $0.59)
• Q1 revenue: $1.35-1.43 billion
• Operating margins target: 27-28%

Buy/Sell Recommendation

SELL recommendation based on:

1. Persistent insider selling with no offsetting purchases
2. Institutional investors reducing positions
3. Trading below key moving averages
4. Limited upside potential given current valuation

Price Targets:

• Support level: $71.03 (Fibonacci S1)
• Resistance level: $76.10 (Fibonacci R1)

Based on the provided data and recent analyst reports, here's a price prediction for Edwards Lifesciences (EW) stock in 2025:

Technical Analysis

• Current price: $74.33 (pre-market)
• Key resistance levels: $76.10, $77.67, $80.20 (Fibonacci)
• Key support levels: $71.03, $69.47, $66.93 (Fibonacci)
• RSI (14) at 51.71 indicates neutral momentum
• MACD showing positive divergence with MACD (0.81) > Signal (0.56)

Fundamental Catalysts

• Stifel upgraded EW to Buy with $90 price target in January 2025
• Strong Q4 2024 results with sales beating estimates at $1.39B
• Three key growth drivers for 2025:
  1. TAVR (Transcatheter Aortic Valve Replacement)
  2. Mitral and Tricuspid therapies
  3. Emerging opportunities in Structural Heart Failure and Aortic Regurgitation

Price Target 2025: $85-90 Reasoning:

1. TAVR growth expected to re-accelerate to 5-7% in 2025
2. FDA likely to expand asymptomatic severe AS TAVR label mid-2025
3. Operating margin expansion of 27-28% expected in 2025
4. Sale of Critical Care business could lead to higher valuation multiples

The stock is likely to reach $85-90 by end of 2025, representing ~15-20% upside from current levels, driven by TAVR growth acceleration, label expansion, and margin improvements.

The S1 support level for EW Stock is $71.28 ,The R1 resistant level for EW Stock is $76.18.

As of the end of day on 2025-02-25, the price of EW Stock was $71.01.

The target price for EW Stock according to analyst rating is 79.17, with the highest price target at 90.00 and the lowest at 60.00. Analysts have a Moderate Buy rating on EW Stock overall.

The market cap of EW is $42.1B.

Based on the provided data and recent analyst coverage, Edwards Lifesciences (EW) appears fairly valued at current levels. The stock's P/E ratio has increased from 30.6x to 33.1x year-over-year, suggesting slightly stretched valuations compared to historical levels. Technical indicators show neutral momentum with RSI at 51.71 and the stock trading between its key moving averages, while the Bollinger Band position (0.55) indicates moderate upside potential. Recent analyst consensus price target of $80.64 implies about 8.5% upside from current levels, with 7 out of 11 analysts maintaining bullish or somewhat bullish ratings. The company's solid revenue growth of 8.93% and strong margins demonstrate fundamental strength, though current valuation multiples largely reflect these positive factors.

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. It conducts operations worldwide and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. It sells products that are used to treat advanced cardiovascular disease in all regions.

Based on the available data and market analysis, here is the price prediction for Edwards Lifesciences (EW) stock by 2030:

Technical Analysis

The stock is currently trading around $74, showing a consolidation pattern after recent volatility. The technical indicators suggest a neutral to slightly bullish bias in the near term.

Fundamental Drivers & Growth Catalysts

According to analyst reports, key growth drivers for EW through 2030 include:

• Strong adoption of Transcatheter Aortic Valve Replacement (TAVR) technology
• Expansion in Mitral and Tricuspid Therapies market
• New opportunities in Structural Heart Failure and Aortic Regurgitation
• Operating margin expansion target of 27-28% by 2025 with further improvements thereafter

2030 Price Target Analysis

Based on the available research and growth projections:

Base Case ($115-125):

• 8-9% annual revenue growth
• Continued market leadership in TAVR
• Successful expansion into new markets
• Operating margin reaching ~30%

Bull Case ($140-150):

• 10% annual revenue growth

• Faster than expected TAVR adoption globally
• Higher margins from operational efficiency
• New product innovations driving growth

Bear Case ($85-95):

• 5-6% annual revenue growth
• Increased competition pressuring margins
• Slower adoption in emerging markets
• Regulatory/reimbursement headwinds

Most Likely Scenario: Base case target of $120 by 2030, representing a ~62% upside from current levels or ~8% compound annual return. This is supported by EW's strong market position, consistent innovation track record, and expanding addressable markets.

EW has a total of 19800 employees.